PharVision Advisers’s Americold COLD Stock Holding History

PharVision Advisers’s Portfolio COLD Stock Details COLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,714	Closed	-$524K	–	221
2025 Q4	$524K	Buy	+40,714	New	+$499K	0.27%	31

Other funds holding COLD

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAMU

APG Asset Management US New York $14.3B AUM 16.79% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

PharVision Advisers's COLD Position: Q1 2026 in Review

PharVision Advisers sold out of Americold (COLD) in Q1 2026, closing a stake of 40,714 shares — an estimated $524K sold.

PharVision Advisers first reported a position in COLD in Q4 2025 and held it in 1 quarter. The position peaked at $524K in Q4 2025. 399 funds tracked by Wall St. Rank hold COLD as of Q1 2026.

PharVision Advisers reported no remaining Americold position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 40,714 Americold shares in Q1 2026, an estimated $524K.
PharVision Advisers first reported a position in Americold in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Americold position peaked at $524K in Q4 2025.
399 funds tracked by Wall St. Rank held Americold as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.